Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Pulse Biosciences (PLSE) EBIT (2020 - 2025)

Pulse Biosciences has reported EBIT over the past 6 years, most recently at -$20.4 million for Q3 2025.

  • Quarterly results put EBIT at -$20.4 million for Q3 2025, down 49.15% from a year ago — trailing twelve months through Sep 2025 was -$78.9 million (down 62.68% YoY), and the annual figure for FY2025 was $72.8 million, up 229.41%.
  • EBIT for Q3 2025 was -$20.4 million at Pulse Biosciences, roughly flat from -$20.3 million in the prior quarter.
  • Over the last five years, EBIT for PLSE hit a ceiling of -$8.7 million in Q4 2022 and a floor of -$20.4 million in Q3 2025.
  • Median EBIT over the past 5 years was -$14.3 million (2021), compared with a mean of -$14.7 million.
  • Biggest five-year swings in EBIT: skyrocketed 44.64% in 2023 and later crashed 72.91% in 2025.
  • Pulse Biosciences' EBIT stood at -$15.4 million in 2021, then skyrocketed by 43.25% to -$8.7 million in 2022, then tumbled by 43.32% to -$12.5 million in 2023, then crashed by 61.66% to -$20.3 million in 2024, then decreased by 0.52% to -$20.4 million in 2025.
  • The last three reported values for EBIT were -$20.4 million (Q3 2025), -$20.3 million (Q2 2025), and -$18.0 million (Q1 2025) per Business Quant data.